Groene Hart Ziekenhuis

The Groene Hart Ziekenhuis is conducting a broad program focused on cardiovascular disease, aiming to test new therapies that lower the risk of heart attacks, strokes, and related events in high‑risk patients.

• IL‑6 inhibition with ziltivekimab for early post‑myocardial infarction care
• Lipoprotein(a) reduction using pelacarsen
• RNA‑based therapy lepodisiran to lower Lp(a) levels
• Inclisiran to achieve sustained LDL‑C lowering
• Combination of vicadrostat and empagliflozin for heart failure with preserved ejection fraction
• Low‑dose colchicine to reduce peripheral artery disease events

With over thirty active trials and more than twenty investigators, the site seeks to improve outcomes for adults at high cardiovascular risk, including those with elevated lipoprotein(a) or recent myocardial infarction.

A diverse set of trials at the hospital targets major cancers, evaluating innovative drug combinations and treatment strategies to extend survival and enhance quality of life for patients with advanced disease.

• Targeted therapy for triple‑negative breast cancer
• Combination of ibrutinib and venetoclax in chronic lymphocytic leukemia
• Reduced‑dose chemotherapy versus standard dosing in metastatic colorectal cancer
• Non‑steroidal aromatase inhibitor plus CDK4/6 inhibition in hormone‑receptor positive breast cancer
• Immunotherapy with pembrolizumab in non‑small cell lung cancer
• Pelacarsen long‑term safety in patients with established cardiovascular disease and solid tumors

The oncology portfolio includes both early‑stage and refractory settings, with a focus on personalized medicine and minimizing treatment‑related toxicity.

Research in the neurology division investigates disease‑modifying approaches for multiple sclerosis, comparing biologic agents and dosing regimens to improve patient outcomes.

• Rituximab versus ocrelizumab in relapsing MS
• Personalized ocrelizumab dosing schedules
• Evaluation of treatment‑free intervals after daratumumab‑lenalidomide therapy

These studies aim to reduce relapse rates and disability progression while assessing safety and patient convenience.

The hematology program at Groene Hart Ziekenhuis explores novel regimens for blood cancers, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and related disorders.

• Venetoclax maintenance versus MRD‑guided venetoclax in CLL
• Acalabrutinib combined with venetoclax for MRD‑negative remission
• BGB‑16673 versus pirtobrutinib in relapsed/refractory CLL and SLL
• Non‑inferiority of reduced‑dose pembrolizumab in advanced NSCLC with hematologic focus

The goal is to identify therapies that achieve deep remissions with manageable side‑effects, supporting patients who are unfit for intensive chemotherapy.

Dedicated studies address female urogenital diseases and reproductive health, testing medical and procedural options to improve symptoms and fertility outcomes.

• Uterine fibroid treatment comparison: ulipristal versus surgery
• Letrozole continuation versus gonadotropin stimulation for PCOS
• Quality‑of‑life assessment after fibroid therapy

By evaluating both pharmacologic and surgical approaches, the site seeks to expand evidence‑based options for women facing these common conditions.

The hospital also conducts research on respiratory tract diseases, focusing on how adjunctive therapies can reduce cardiovascular complications in patients with acute infections.

• Aspirin added to standard care in community‑acquired pneumonia or influenza
• Prevention of opioid‑induced constipation in advanced cancer patients
• Evaluation of dexamethasone omission in paclitaxel premedication regimens

These investigations aim to enhance safety and outcomes for patients hospitalized with serious respiratory illnesses while addressing supportive care needs.